Disease Modifying Anti-rheumatic Drugs,DMARDs Mycophenolate Pharmacology Physiotherapy

Mycophenolate and Cholestyramine

In this article we will discuss Mycophenolate and Cholestyramine

In this article, we will discuss Mycophenolate and Cholestyramine. So, let’s get started.

Mycophenolate and Cholestyramine

Following single-dose administration of 1.5 g mycophenolate mofetil to 12 healthy
volunteers pretreated with 4 g tid of cholestyramine for 4 days, MPA AUC decreased approximately 40%. This decrease is consistent with interruption of enterohepatic recirculation which may be due to binding of recirculating MPAG with cholestyramine in the intestine. Some degree of enterohepatic recirculation is also anticipated following intravenous administration of mycophenolate. Therefore, mycophenolate is not recommended to be given with cholestyramine or other agents that may interfere with enterohepatic

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.